Insider Selling: Becton, Dickinson and Company (NYSE:BDX) EVP Sells 75 Shares of Stock

Key Points

• Insider sale: Becton, Dickinson EVP Michael Feld sold 75 shares at an average price of $147.35, worth about $11,051. The sale was made under a pre-arranged Rule 10b5-1 trading plan and reduced his holdings by just 0.35%.
• Recent performance and earnings: The company reported quarterly EPS of $2.90, topping estimates of $2.77, on revenue of $4.71 billion, which also beat expectations. Revenue rose 5.2% year over year, and BDX set FY 2026 EPS guidance of 12.52 to 12.72.
• Dividend and analyst outlook: Becton, Dickinson declared a quarterly dividend of $1.05 per share, implying a 2.9% yield. Wall Street’s consensus rating is Hold, with a median price target of $184.86.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) EVP Michael Feld sold 75 shares of the business's stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $147.35, for a total transaction of $11,051.25. Following the completion of the transaction, the executive vice president owned 21,084 shares in the company, valued at approximately $3,106,727.40. The trade was a 0.35% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Feld also recently made the following trade(s):

• On Monday, April 27th, Michael Feld sold 74 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $151.94, for a total transaction of $11,243.56.
• On Thursday, February 26th, Michael Feld sold 75 shares of Becton, Dickinson and Company stock. The shares were sold at an average price of $181.84, for a total transaction of $13,638.00.

Becton, Dickinson and Company Stock Performance

BDX traded down $1.06 during midday trading on Wednesday, reaching $146.70. The company had a trading volume of 1,759,620 shares, compared to its average volume of 2,879,161. The business has a 50-day moving average price of $152.37 and a two-hundred day moving average price of $177.65. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $187.35. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.94. The stock has a market cap of $40.42 billion, a PE ratio of 37.11, a P/E/G ratio of 10.45 and a beta of 0.22.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The medical instruments supplier reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.77 by $0.13. Becton, Dickinson and Company had a net margin of 5.33% and a return on equity of 15.37%. The company had revenue of $4.71 billion for the quarter, compared to analyst estimates of $4.67 billion. During the same quarter in the previous year, the firm posted $3.35 earnings per share. The company's quarterly revenue was up 5.2% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.520-12.720 EPS. On average, sell-side analysts expect that Becton, Dickinson and Company will post 12.61 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase plan on Tuesday, January 27th that allows the company to repurchase $10.00 million in outstanding shares. This repurchase authorization allows the medical instruments supplier to buy up to 0% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company's leadership believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 30th. Stockholders of record on Tuesday, June 9th will be given a $1.05 dividend. The ex-dividend date of this dividend is Tuesday, June 9th. This represents a $4.20 annualized dividend and a dividend yield of 2.9%. Becton, Dickinson and Company's payout ratio is 106.33%.

Institutional Trading of Becton, Dickinson and Company

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Brighton Jones LLC increased its holdings in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier's stock worth $401,000 after buying an additional 877 shares during the last quarter. Oppenheimer Asset Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 71.4% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 82,655 shares of the medical instruments supplier's stock valued at $15,471,000 after purchasing an additional 34,437 shares in the last quarter. Transcend Capital Advisors LLC boosted its stake in shares of Becton, Dickinson and Company by 88.2% in the 3rd quarter. Transcend Capital Advisors LLC now owns 5,794 shares of the medical instruments supplier's stock valued at $1,084,000 after purchasing an additional 2,715 shares in the last quarter. Assetmark Inc. boosted its stake in shares of Becton, Dickinson and Company by 49.5% in the 3rd quarter. Assetmark Inc. now owns 225,967 shares of the medical instruments supplier's stock valued at $42,294,000 after purchasing an additional 74,795 shares in the last quarter. Finally, Belpointe Asset Management LLC purchased a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at $650,000. Institutional investors own 86.97% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. Zacks Research raised shares of Becton, Dickinson and Company from a "strong sell" rating to a "hold" rating in a research report on Friday, April 10th. Stifel Nicolaus decreased their target price on shares of Becton, Dickinson and Company from $215.00 to $175.00 in a report on Thursday, May 7th. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a report on Tuesday, April 14th. Wells Fargo & Company upped their target price on shares of Becton, Dickinson and Company from $157.00 to $161.00 and gave the stock an "equal weight" rating in a report on Friday, May 8th. Finally, Weiss Ratings lowered shares of Becton, Dickinson and Company from a "hold (c-)" rating to a "sell (d+)" rating in a report on Monday, May 11th. Seven analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Hold" and a consensus price target of $184.86.

About Becton, Dickinson and Company

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.